Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy
10.3760/cma.j.cn501113-20201124-00628
- VernacularTitle:接受过抗病毒治疗的乙型肝炎相关肝细胞癌患者合并代谢性疾病的比例更高
- Author:
Zhou ZHAO
1
;
Kaifeng WANG
;
Li CHEN
;
Qiuhong YOU
;
Yaobo WU
;
Jian SUN
Author Information
1. 器官衰竭防治国家重点实验室 广东省病毒性肝炎研究重点实验室 南方医科大学南方医院感染内科，广州 510515
- Keywords:
Hepatitis B;
Metabolic diseases;
Antiviral therapy;
Hepatocellular carcinoma
- From:
Chinese Journal of Hepatology
2021;29(4):344-349
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the proportion of hepatitis B-related hepatocellular carcinoma (HCC) patients who have received antiviral therapy and compare the clinical characteristics of HCC patients who have received antiviral therapy with those who have not received antiviral therapy.Methods:Data of 2590 newly diagnosed hepatitis B-related HCC cases who were hospitalized in Nanfang Hospital from 2015 to 2017 were collected. Two independent sample t-tests, Mann-Whitney U test, and χ2 test were used to compare the clinical characteristics of hepatitis B-related HCC patients who had received antiviral therapy and those who had not received antiviral therapy. Propensity score was used to match some clinical characteristics of the two groups of patients, and the differences in clinical characteristics of the two groups of patients after matching were further compared. Patients with HCC who had not received antiviral therapy were used as reference, and then the clinical characteristics of HCC patients who had received antiviral treatment were analyzed using multivariate logistic regression. Results:Among the 2 590 patients with hepatitis B-related HCC, only 18.10% of patients had received antiviral therapy, while 82.20% of patients who did not receive antiviral therapy met the treatment criteria. HCC patients who had received antiviral therapy were older ( P < 0.05), had a higher proportion of liver cirrhosis ( P < 0.001), and lower levels of platelets and alanine aminotransferases and smaller maximum tumor diameter ( P < 0.001). In terms of metabolic disease, patients who had received antiviral treatment had higher prevalence of diabetes (14.50% vs. 7.70%, P < 0.001), hypertension (16.60% vs. 11.20%, P < 0.05), obesity (28.50% vs. 22.30%, P < 0.05), overweight (53.80% vs. 43.50%, P < 0.001) and non-alcoholic fatty liver disease (18.30% vs.8.00%, P < 0.001). After matching other different clinical characteristics, the prevalence of diabetes, hypertension, and non-alcoholic fatty liver disease in patients who received antiviral therapy was still higher than that of patients who did not receive antiviral therapy (14.50% vs. 9.80%, P < 0.05; 16.60% vs. 10.20%, P < 0.05; 18.30% vs. 7.00%, P < 0.001). Multivariate logistic regression analysis showed that HCC patients who had received antiviral therapy had a higher risk of developing non-alcoholic fatty liver disease ( OR: 2.054, 95% CI: 1.404~3.004) than those who had not received antiviral therapy. Conclusion:Among patients with hepatitis B-related HCC, the proportion of patients who have received antiviral therapy is significantly low (under 20%), which suggests that the popularization and promotion of antiviral therapy has a long way to go. Compared with HCC patients who have not received antiviral therapy, the proportion of HCC patients who have received antiviral therapy combined with metabolic diseases is higher; therefore, it is necessary to pay more attention to the role of metabolic factors in the pathogenesis of hepatitis B-related HCC.
